DK0603992T4 - Oral indgivelse af immunologisk aktive biomolekyler og andre terapeutiske proteiner - Google Patents

Oral indgivelse af immunologisk aktive biomolekyler og andre terapeutiske proteiner

Info

Publication number
DK0603992T4
DK0603992T4 DK93300005T DK93300005T DK0603992T4 DK 0603992 T4 DK0603992 T4 DK 0603992T4 DK 93300005 T DK93300005 T DK 93300005T DK 93300005 T DK93300005 T DK 93300005T DK 0603992 T4 DK0603992 T4 DK 0603992T4
Authority
DK
Denmark
Prior art keywords
protein
therapeutic protein
orally
oral administration
stabilizing agent
Prior art date
Application number
DK93300005T
Other languages
Danish (da)
English (en)
Other versions
DK0603992T3 (da
Inventor
J Gabriel Michael
Allen Litwin
Original Assignee
Univ Cincinnati
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25541237&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0603992(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Cincinnati filed Critical Univ Cincinnati
Publication of DK0603992T3 publication Critical patent/DK0603992T3/da
Application granted granted Critical
Publication of DK0603992T4 publication Critical patent/DK0603992T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A61K39/36—Allergens from pollen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DK93300005T 1992-12-22 1993-01-04 Oral indgivelse af immunologisk aktive biomolekyler og andre terapeutiske proteiner DK0603992T4 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US99493292A 1992-12-22 1992-12-22

Publications (2)

Publication Number Publication Date
DK0603992T3 DK0603992T3 (da) 1997-03-24
DK0603992T4 true DK0603992T4 (da) 2001-03-05

Family

ID=25541237

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93300005T DK0603992T4 (da) 1992-12-22 1993-01-04 Oral indgivelse af immunologisk aktive biomolekyler og andre terapeutiske proteiner

Country Status (12)

Country Link
US (1) US5591433A (ja)
EP (1) EP0603992B2 (ja)
JP (1) JPH0710771A (ja)
AT (1) ATE143803T1 (ja)
AU (1) AU664222B2 (ja)
CA (1) CA2086631C (ja)
DE (1) DE69305313T3 (ja)
DK (1) DK0603992T4 (ja)
ES (1) ES2095001T5 (ja)
GR (2) GR3022090T3 (ja)
NZ (1) NZ245618A (ja)
SG (1) SG52402A1 (ja)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06508371A (ja) * 1991-06-21 1994-09-22 ユニバーシティー オブ シンシナティ 経口投与できる治療用タンパク質及びその製法
US6613332B1 (en) 1991-06-21 2003-09-02 The University Of Cincinnati Oral administration of therapeutic proteins
US6083503A (en) * 1991-08-28 2000-07-04 The United States Of America As Represented By The Department Of Health And Human Services Interleukin-2 stimulated T lymphocyte cell death for the treatment of autoimmune diseases, allergic responses, and graft rejection
CA2187345A1 (en) * 1994-04-08 1995-10-19 Howard L. Weiner Treatment of autoimmune disease using oral tolerization and/or th2-enhancing cytokines
US20030202980A1 (en) * 1995-12-29 2003-10-30 Caplan Michael J. Methods and reagents for decreasing clinical reaction to allergy
US5980948A (en) * 1996-08-16 1999-11-09 Osteotech, Inc. Polyetherester copolymers as drug delivery matrices
WO1998007443A1 (fr) * 1996-08-20 1998-02-26 Freund Industrial Co., Ltd. Microspheres contenant des immunogenes, procede de fabrication et procede permettant d'immuniser des animaux a l'aide de ces microspheres
CN1228708A (zh) * 1996-09-04 1999-09-15 有限会社多特 经口给药用含肽药物组合物
US8828432B2 (en) 1996-10-28 2014-09-09 General Mills, Inc. Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles
US6559158B1 (en) 1997-11-03 2003-05-06 Ur Labs, Inc. Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
US6274591B1 (en) * 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
AU743647B2 (en) * 1998-01-31 2002-01-31 Mt. Sinai School Of Medicine Of New York University Methods and reagents for decreasing allergic reactions
US7879977B2 (en) 1998-01-31 2011-02-01 University Of Arkansas Methods and reagents for decreasing clinical reaction to allergy
US6328967B1 (en) * 1998-03-12 2001-12-11 Allergenics, Inc. Delivery system to modulate immune response
US7201923B1 (en) 1998-03-23 2007-04-10 General Mills, Inc. Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles
DE69941212D1 (de) 1998-03-23 2009-09-17 Gen Mills Inc Verkapselung von komponenten in essbaren produkten
SE9801288D0 (sv) * 1998-04-14 1998-04-14 Astra Ab Vaccine delivery system and metod of production
GB9818591D0 (en) * 1998-08-27 1998-10-21 Danbiosyst Uk Pharmaceutical composition
WO2000054797A2 (en) 1999-03-17 2000-09-21 Novartis Ag Pharmaceutical compositions comprising tgf-beta
US6500463B1 (en) 1999-10-01 2002-12-31 General Mills, Inc. Encapsulation of sensitive components into a matrix to obtain discrete shelf-stable particles
WO2001051008A2 (en) * 2000-01-07 2001-07-19 University Of Cincinnati Selective activation of a th1 or th2 lymphocyte regulated immune response
DK1272213T3 (da) * 2000-04-06 2006-07-10 Seer Pharmaceuticals Llc Mikrobielt afgivelsessystem
US8246945B2 (en) * 2000-04-06 2012-08-21 University Of Arkansas Methods and reagents for decreasing clinical reaction to allergy
US20050063994A1 (en) * 2000-04-06 2005-03-24 Caplan Michael J. Methods and reagents for decreasing clinical reaction to allergy
US6436453B1 (en) 2000-06-16 2002-08-20 General Mills, Inc. Production of oil encapsulated minerals and vitamins in a glassy matrix
US6468568B1 (en) 2000-06-16 2002-10-22 General Mills, Inc. Oligosaccharide encapsulated mineral and vitamin ingredients
US6558718B1 (en) 2000-06-19 2003-05-06 General Mills, Inc. Nutrient clusters for food products and methods of preparation
EP2343317A1 (en) 2000-11-10 2011-07-13 F. Hoffmann-La Roche Ltd. Apolipoprotein analogues
DE60234183D1 (de) * 2001-06-05 2009-12-10 Univ Chicago Verwendung von methylnaltrexon zur behandlung von immunsuppression
SK1732004A3 (sk) * 2001-10-15 2005-06-02 R�Hm Gmbh & Co. Kg Použitie kopolyméru na prípravu liekovej formy, ktorá ako účinnú látku obsahuje peptid alebo proteín
KR100469943B1 (ko) * 2002-03-20 2005-02-02 삼성정밀화학 주식회사 장용성 코팅제로 사용되는 아크릴 공중합체의 제조 방법
US20040043070A1 (en) * 2002-05-14 2004-03-04 Ayres James W. Hot melt coating by direct blending and coated substrates
US7431986B2 (en) 2002-07-24 2008-10-07 General Mills, Inc. Encapsulation of sensitive components using pre-emulsification
WO2004091665A1 (en) * 2003-04-08 2004-10-28 Progenics Pharmaceuticals, Inc. Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist
EP2368554B1 (en) 2003-04-08 2014-12-24 Progenics Pharmaceuticals, Inc. Pharmaceutical formulations containing methylnaltrexone
EP1617846A1 (en) * 2003-04-08 2006-01-25 Progenics Pharmaceuticals, Inc. The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome
US20070141071A1 (en) * 2003-05-14 2007-06-21 Oregon State University Hot melt coating by direct blending and coated substrates
WO2005123119A2 (en) * 2004-06-10 2005-12-29 Catalyst Biosciences, Inc. Administration of neutral endopeptidase to treat inflammatory bowel disease
WO2005123120A1 (en) * 2004-06-16 2005-12-29 Smart Drug Systems Inc. Sustained release vaccine composition
MX2007008756A (es) * 2005-01-20 2007-09-27 Progenics Pharm Inc Uso de metilnaltrexona y compuestos relacionados para el tratamiento de disfuncion gastrointestinal postoperatoria.
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US8524731B2 (en) * 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662390B2 (en) * 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057035A1 (es) * 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) * 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
US20080194611A1 (en) * 2005-06-03 2008-08-14 Alverdy John C Modulation of Cell Barrier Dysfunction
AU2006299310A1 (en) 2005-10-04 2007-04-12 Alk-Abello A/S Solid vaccine formulation
US7803413B2 (en) 2005-10-31 2010-09-28 General Mills Ip Holdings Ii, Llc. Encapsulation of readily oxidizable components
WO2007112747A1 (en) * 2006-03-31 2007-10-11 Curalogic A/S Immunogen combinations
TW200817048A (en) * 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
EP3263571B2 (en) * 2007-03-29 2023-08-23 Progenics Pharmaceuticals, Inc. Crystal form of (r)-n-methylnaltrexone bromide and uses thereof
PE20130480A1 (es) * 2007-03-29 2013-05-08 Progenics Pharm Inc Compuestos heterociclicos como antagonistas del receptor opioide periferico
MX2009010515A (es) * 2007-03-29 2009-10-19 Wyeth Corp Antagonistas del receptor opioide periferico y usos de los mismos.
CA2713568C (en) * 2008-02-06 2016-09-20 Progenics Pharmaceuticals, Inc. Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
EP2278966B1 (en) 2008-03-21 2019-10-09 The University of Chicago Treatment with opioid antagonists and mtor inhibitors
CA2726193C (en) 2008-06-03 2018-11-27 University Of Rochester Methods of treating inflammatory intestinal disease and managing symptoms thereof
WO2010002576A1 (en) 2008-07-01 2010-01-07 University Of Chicago Particles containing an opioid receptor antagonist and methods of use
JP2010077057A (ja) * 2008-09-25 2010-04-08 Kagoshima Univ 抗食物アレルギーワクチン
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
JP5931449B2 (ja) * 2012-01-11 2016-06-08 日東電工株式会社 医薬組成物及びその製造方法
US10940170B2 (en) 2014-07-07 2021-03-09 University Of Massachusetts Anthelmintic probiotic compositions and methods
CN107249327A (zh) 2014-10-17 2017-10-13 萨利克斯药品公司 使用甲基纳曲酮减缓肿瘤进展
US11484568B2 (en) 2016-01-15 2022-11-01 University Of Massachusetts Anthelmintic compositions and methods
CN117752694A (zh) 2017-05-23 2024-03-26 马萨诸塞大学 经纯化的抗蠕虫组合物及相关方法
WO2020106704A2 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
WO2020257017A1 (en) 2019-06-18 2020-12-24 Progenity, Inc. Ingestible device with component capable of residing in the gastrointestinal tract
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE621398A (ja) * 1900-01-01
US3143473A (en) * 1961-08-16 1964-08-04 Behringwerke Ag Stable, solid, oral live antipoliomyelitis vaccine compositions and process for preparing them
US3458621A (en) * 1966-08-31 1969-07-29 American Home Prod Tablet dosage-form for the immunization of the intestinal tract with live virus preparations
US3909444A (en) * 1971-08-05 1975-09-30 Ncr Co Microcapsule
US3823228A (en) * 1971-09-29 1974-07-09 Univ Illinois Tge virus vaccine
US3860490A (en) * 1972-02-11 1975-01-14 Nat Patent Dev Corp Process of subjecting a microorganism susceptible material to a microorganism
US3767790A (en) * 1972-02-11 1973-10-23 Nat Patent Dev Corp Microorganisms
US4016254A (en) * 1972-05-19 1977-04-05 Beecham Group Limited Pharmaceutical formulations
JPS517116A (en) * 1974-06-11 1976-01-21 Shinetsu Chemical Co Choyoseihifukuyakuzaino seizohoho
US4269764A (en) * 1979-08-02 1981-05-26 Roy Patterson Preparation for treatment of allergic patients sensitive to ragweed pollen
US4469677A (en) * 1980-02-19 1984-09-04 Michael J Gabriel Polypeptide active immunosuppressant fraction
JPS5855125B2 (ja) * 1980-03-10 1983-12-08 信越化学工業株式会社 固形薬剤用腸溶性コ−テイング剤組成物
JPS56142211A (en) * 1980-04-09 1981-11-06 Riken Vitamin Co Ltd Production of enteric preparation
US4348384A (en) * 1980-10-17 1982-09-07 Dainippon Pharmaceutical Co., Ltd. Pharmaceutical composition for oral administration containing coagulation factor VIII or IX
US4507276A (en) * 1982-08-20 1985-03-26 Bristol-Myers Company Analgesic capsule
SE8303401D0 (sv) * 1983-06-15 1983-06-15 Pharmacia Ab Beredning och dess anvendning
GB8321178D0 (en) * 1983-08-05 1983-09-07 Beecham Group Plc Compositions
US4704295A (en) * 1983-09-19 1987-11-03 Colorcon, Inc. Enteric film-coating compositions
US4794000A (en) * 1987-01-08 1988-12-27 Synthetic Blood Corporation Coacervate-based oral delivery system for medically useful compositions
DE3431861A1 (de) * 1984-08-30 1986-03-13 Troponwerke GmbH & Co KG, 5000 Köln Pellet-zubereitung
ZA858044B (en) * 1984-11-01 1987-05-27 American Home Prod Oral vaccines
EP0192321A3 (en) * 1985-01-19 1987-09-02 Beecham Group Plc Enteric coated allergen pharmaceutical composition
CH663900A5 (de) * 1985-05-06 1988-01-29 Cernitin Sa Pharmazeutisches praeparat zur prophylaktischen behandlung von allergien und verfahren zur herstellung dieses praeparates.
IL78775A (en) * 1985-05-15 1992-06-21 Biotech Australia Pty Ltd Oral vaccines
GB8519310D0 (en) * 1985-07-31 1985-09-04 Zyma Sa Granular active substances
US4820627A (en) * 1986-03-24 1989-04-11 Em Diagnostic Systems, Inc. Method of preparing particles suitable for tabletting into diagnostic reagents
JPH0759496B2 (ja) * 1986-03-25 1995-06-28 ロ−ト製薬株式会社 歯周病治療剤
US5075109A (en) * 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
FR2609895B1 (fr) * 1987-01-28 1991-06-28 Bruttmann Georges Nouvelles formes galeniques d'allergenes pour administration par voie per- et sub-linguale
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
JPS6417A (en) * 1987-02-20 1989-01-05 Shikoku Chem Corp Chemotherapeutic agent composition
US4874613A (en) * 1987-03-06 1989-10-17 Baker Cummins Pharmaceuticals, Inc. Taste concealing pharmaceutical dosage unit
US5116612A (en) * 1987-06-23 1992-05-26 Allergy Immuno Technologies, Inc. Immunotherapy agents for treatment of IgE mediated allergies
US4946945A (en) * 1987-06-23 1990-08-07 Allergy Immuno Technologies, Inc. Immunotherapy agents for treatment of IgE mediated allergies
US5049390A (en) * 1987-09-02 1991-09-17 Allergy Immuno Technologies, Inc. Liposome containing immunotherapy agents for treating IgE mediated allergies
IL87710A (en) * 1987-09-18 1992-06-21 Ciba Geigy Ag Covered floating retard form for controlled release in gastric juice
US5236713A (en) * 1987-10-21 1993-08-17 Teikoku Seiyaku Kabushiki Kaisha Preparation for intermittently releasing active agent applicable to oral cavity
GB8826116D0 (en) * 1988-11-08 1988-12-14 Danbiosyst Ltd Adhesive drug delivery composition
WO1990011070A1 (en) * 1989-03-17 1990-10-04 Pitman-Moore, Inc. Controlled release delivery device for macromolecular proteins
US5047258A (en) * 1989-07-14 1991-09-10 Sterling Drug Inc. Aqueous spray-coating process
US5032405A (en) * 1989-09-27 1991-07-16 Warner-Lambert Company Oral pharmaceutical composition for acid sensitive proteinaceous agents
AU7908791A (en) * 1990-05-08 1991-11-27 Liposome Technology, Inc. Direct spray-dried drug/lipid powder composition
US5149543A (en) * 1990-10-05 1992-09-22 Massachusetts Institute Of Technology Ionically cross-linked polymeric microcapsules
JP2635444B2 (ja) * 1990-10-15 1997-07-30 オートイミューン インク 自己抗体の経口投与による自己免疫性疾患の治療
JPH04230625A (ja) * 1990-12-27 1992-08-19 Standard Chem & Pharmaceut Corp Ltd 噴霧乾燥したジクロフェナクナトリウムを含み腸溶性の被覆を有するマイクロカプセルからなる微分散した錠剤組成物の製造方法
JPH06508371A (ja) † 1991-06-21 1994-09-22 ユニバーシティー オブ シンシナティ 経口投与できる治療用タンパク質及びその製法
US5160742A (en) * 1991-12-31 1992-11-03 Abbott Laboratories System for delivering an active substance for sustained release

Also Published As

Publication number Publication date
ATE143803T1 (de) 1996-10-15
GR3035452T3 (en) 2001-05-31
ES2095001T5 (es) 2001-03-16
EP0603992B1 (en) 1996-10-09
AU3104593A (en) 1994-07-07
EP0603992A1 (en) 1994-06-29
ES2095001T3 (es) 1997-02-01
DK0603992T3 (da) 1997-03-24
SG52402A1 (en) 1998-09-28
DE69305313T3 (de) 2001-06-21
AU664222B2 (en) 1995-11-09
DE69305313T2 (de) 1997-02-20
JPH0710771A (ja) 1995-01-13
US5591433A (en) 1997-01-07
NZ245618A (en) 1994-10-26
DE69305313D1 (de) 1996-11-14
EP0603992B2 (en) 2000-12-06
CA2086631A1 (en) 1994-06-23
CA2086631C (en) 1998-10-06
GR3022090T3 (en) 1997-03-31

Similar Documents

Publication Publication Date Title
DK0603992T4 (da) Oral indgivelse af immunologisk aktive biomolekyler og andre terapeutiske proteiner
ATE158180T1 (de) Oral verabreichbare therapeutische proteine und herstellungsverfahren
RU93004764A (ru) Амиды сульфамидо- и сульфамидокарбонилпиридин-2-карбоновых кислот, их пиридин-n-оксиды, способ их получения и их применение в качестве лекарственных препаратов
NO964864D0 (no) Orale, flytende alendronatpreparater
MX9304346A (es) Composicion de vacuna oral para especies rumiantes y metodo para su produccion.
CY1107571T1 (el) Αυξητικος παραγοντας νευρων ως βοηθητικη ουσια εμβολιου
NO157145C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive n-glykosylerte karboksylsyreamidderivater.
SE8505569D0 (sv) Enteralt preparat
DE69031351D1 (de) Zubereitungen und behandlungen von pneumonia in tieren
GR3004069T3 (ja)
RU1808324C (ru) Способ профилактики и лечени казеинобезоарной болезни новорожденных гн т
SE8200748L (sv) Terapeutiskt medel
DE2640707C3 (de) Verfahren zur Herstellung von Arzneipräparaten mit einem Gehalt an von im Darm resorbierbaren Protein und Peptidlösungen
RU94028204A (ru) Препарат "уберсан" для лечения мастита у сельскохозяйственных животных
RU93009804A (ru) Вакцина против эшерихиоза животных
RU2000104571A (ru) Способ коррекции иммунной недостаточности при желудочно-кишечных заболеваниях поросят
SU1237214A1 (ru) Вакцина дл профилактики л рвальных тениидозов сельскохоз йственных животных
SE9003096D0 (sv) Device for administering a physiologically active substance to the gastro-intestinal tract
RU93056259A (ru) Средство для лечения диспепсии телят
RU2001106744A (ru) Способ профилактики и лечения мастита у коров
RU94012402A (ru) Способ лечения синдрома раздраженной кишки
RU2001113054A (ru) Способ лечения послеродового острого гнойно-катарального эндометрита коров
RU95105357A (ru) Способ лечения пищевой аллергии
RU93056258A (ru) Способ лечения диспепсии телят
RU2000126015A (ru) Лекарственное средство для лечения и профилактики болезней, вызываемых недостаточностью селена в организме сельскохозяйственных животных